- Advertisement -
Saturday, 5 December 2020

CHARITY TODAY AWARDS

‘Holy Grail’ discovery to prevent disability in multiple sclerosis

- Advertisement -

A research programme spanning over a decade has discovered a ‘Holy Grail’ molecular target to protect nerves from damage in multiple sclerosis (MS). The paper, published in Acta Neuropathologica, also suggests a common diabetes drug could help enhance this new-found natural mechanism – and prevent disability progression in the neurological condition.

In MS the protective coating that surrounds nerves, known as myelin, is damaged and nerves become less energy efficient as a result. Not having the energy they need makes nerves vulnerable to further damage and causes disability over time.

But for the first time researchers at the University of Edinburgh – funded in part by the MS Society – have discovered a natural mechanism in the body that tackles this issue, which they are calling ARMD (axonal response of mitochondria to demyelination).

Although this natural function alone doesn’t provide enough energy to address demyelination in MS, the discovery raised the possibility of using a drug to enhance it. Further research in animal models now suggests pioglitazone – currently used to treat diabetes – could be the answer.

Dr Don Mahad, Lead Author and Senior Clinical Lecturer at the University of Edinburgh, said:

“Disability in MS is caused by a loss of nerve fibres following damage to the myelin that protects them. Although our understanding of MS has vastly improved over the last two decades, new therapies still do not protect nerve fibres. Such protection is the Holy Grail in MS treatment – not only for the relapsing form of MS, which has various options available but for progressive forms too, where treatment continues to lag behind.

“Our discovery shows that nerves respond to myelin damage by increasing the movement of mitochondria (the cell powerhouse, which produces energy) to the area of damage – a response we’re calling ‘ARMD’. Remarkably, we were able to enhance ARMD and protect these vulnerable nerves using the readily available diabetes drug pioglitazone. This is an incredibly important discovery – one we believe could finally bridge the gap in MS treatment.”

Over the last few decades, there have been huge strides made in our understanding of MS, and there are now over a dozen effective treatments for people with relapsing MS – but these only address damage that is caused by the immune system. In order to truly stop MS and find treatments for everyone, we need to find ways to both protect nerves from further injury and repair damaged myelin.

Last year, another MS Society-funded study found that a different diabetes drug – the fasting mimetic drug metformin – was able to return cells to a more youthful state, and encourage the re-growth of myelin. Led by Professor Robin Franklin, the study found metformin could reverse changes that happen to cells responsible for making myelin as they age, and restore their regenerative capacity.

MS Society Assistant Director of Research, Dr Emma Gray, said:

“This represents another important stride towards our goal of stopping MS – and we believe that MS treatment could in the near future look completely different. People with MS will be prescribed a combination of therapies that work on every aspect of the condition: stopping immune attacks and relapses, protecting nerves from damage, and regenerating lost myelin. It will mean no-one needs to worry about their MS getting worse.

“Currently, there are no effective neuroprotective therapies available for MS, but Dr Mahad’s research demonstrates we are getting closer – and finding treatments for everyone with MS is now a very real prospect.”

Case study

Husband and wife Steve and Jacqueline Tutt both have MS. Steve, 56, has the relapsing form whereas Jacqueline, 62, developed secondary progressive MS after living with relapses for several years. The couple has two grown-up children and live together in Eastbourne.

Steve says: “We used to be really outgoing, gregarious people, always out from Friday to Sunday, partying with our friends. Now we hardly see anyone. My wife is wheelchair-bound and I struggle walking 20 yards unaided. You’re forced to stay inside.

“It’s hard that Jacquie doesn’t have any treatment to help her. In my case, there are all these DMTs you can take, but if you’ve got progressive MS there’s nothing for you. In the past, we became very frustrated. We would read about new DMTs coming out for relapsing MS all the time but there was never anything for my wife.

“It sounds wrong but looking at my wife can be like looking into the future. If I get worse there will be nothing for either of us and what do we do then? This research gives us something to look forward to and be excited about.”

Jacqui lives with symptoms like severe nerve pain and spasticity, where her joints go into spasms without any warning. She relies on a wheelchair to get around. Jacqui says:

“It breaks my heart not having treatment because I’m not the only person living with this – there are so many of us suffering. Right now I’m taking a cocktail of drugs to manage my pain but it doesn’t help really. I’m even on morphine but nothing works at all.

“Stopping my disability progressing would mean the world to me. It would mean I could live life again and be there for the people that need me. It would be a miracle.”

Sign up to receive full FREE access to charity news and special sector offers.

We don’t spam! Read our privacy policy for more info.

- Advertisement -
- Advertisement -

Stay Connected

1,383FansLike
1,834FollowersFollow
30,328FollowersFollow
1,200SubscribersSubscribe

Must Read

VIDEO | UK Charity Week makes Embrace’s single its campaign theme tune

A charity single, written in lockdown to raise money for Embrace Child Victims of Crime, has been adopted by UK Charity Week 2020 as...

Dementia UK Launches ‘Only together’ campaign

'Only together,' the charity's first-ever influencing campaign, highlights the low level of specialist support currently available to families affected by dementia, and how access to quality care could...

Employment News

New CEO at Asthma UK and The British Lung Foundation

SARAH Woolnough has been announced as Chief Executive at Asthma UK and the British Lung Foundation, as the current Chief Executive, Kay Boycott, moves...

Great Britain wheelchair basketball star, Sophie Carrigill becomes patron

SHEFFIELD-based Sophie Carrigill, the Great Britain wheelchair basketball co-captain at the 2016 Rio Olympics, has today, on the UN International Day of People with...

COO Jerry Robinson to move on from leading youth charity YHA

YHA’s Chief Operating Officer Jerry Robinson has announced he is to step down from YHA (England & Wales) at the end of the year,...

Related News

How lockdown affected Lucy’s conductive journey as a first year student

Lucy Meredith is a second-year student on the BA in CE/QCS course at Birmingham City University/NICE Conductive College. Lucy writes: At the beginning of September...

Liverpool-based musician Cal Ruddy performs from home for UK Charity Week

CHARITIES taking part in this year’s UK Charity Week have received a special performance from one of the campaign’s ambassadors. Musician, Cal Ruddy, recorded the...

Sir Stuart Etherington appointed as NatCen’s Chair of Trustees

THE National Centre for Social Research (NatCen) has appointed Sir Stuart Etherington as its Chair of Trustees. Sir Stuart, the former Chief Executive of the...

New CEO at Asthma UK and The British Lung Foundation

SARAH Woolnough has been announced as Chief Executive at Asthma UK and the British Lung Foundation, as the current Chief Executive, Kay Boycott, moves...

Primary school offers Hand of Friendship to Adults with Learning Disabilities

CABRINI House, based in Orpington, a residential home for 23 adults with learning disabilities is run by the charity Diagrama. During the pandemic safely...
- Advertisement -
X